Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Globalization and Health
Published in: Globalization and Health 1/2017

Open Access 01-12-2017 | Research

Global research trends of World Health Organization’s top eight emerging pathogens

Author: Waleed M. Sweileh

Published in: Globalization and Health | Issue 1/2017

Login to get access

Abstract

Background

On December 8th, 2015, World Health Organization published a priority list of eight pathogens expected to cause severe outbreaks in the near future. To better understand global research trends and characteristics of publications on these emerging pathogens, we carried out this bibliometric study hoping to contribute to global awareness and preparedness toward this topic.

Method

Scopus database was searched for the following pathogens/infectious diseases: Ebola, Marburg, Lassa, Rift valley, Crimean-Congo, Nipah, Middle Eastern Respiratory Syndrome (MERS), and Severe Respiratory Acute Syndrome (SARS). Retrieved articles were analyzed to obtain standard bibliometric indicators.

Results

A total of 8619 journal articles were retrieved. Authors from 154 different countries contributed to publishing these articles. Two peaks of publications, an early one for SARS and a late one for Ebola, were observed. Retrieved articles received a total of 221,606 citations with a mean ± standard deviation of 25.7 ± 65.4 citations per article and an h-index of 173. International collaboration was as high as 86.9%. The Centers for Disease Control and Prevention had the highest share (344; 5.0%) followed by the University of Hong Kong with 305 (4.5%). The top leading journal was Journal of Virology with 572 (6.6%) articles while Feldmann, Heinz R. was the most productive researcher with 197 (2.3%) articles. China ranked first on SARS, Turkey ranked first on Crimean-Congo fever, while the United States of America ranked first on the remaining six diseases. Of retrieved articles, 472 (5.5%) were on vaccine – related research with Ebola vaccine being most studied.

Conclusion

Number of publications on studied pathogens showed sudden dramatic rise in the past two decades representing severe global outbreaks. Contribution of a large number of different countries and the relatively high h-index are indicative of how international collaboration can create common health agenda among distant different countries.
Literature
1.
2.
Akinci E, Bodur H, Sunbul M, Leblebicioglu H. Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever. Antivir Res. 2016;132:233–43.PubMedCrossRef
3.
Brackney DE, Armstrong PM. Transmission and evolution of tick-borne viruses. Curr Opin Virol. 2016;21:67–74.PubMedCrossRef
4.
Shayan S, Bokaean M, Shahrivar MR, Chinikar S. Crimean-Congo hemorrhagic fever. Lab Med. 2015;46(3):180–9.PubMedCrossRef
5.
6.
Kaner J, Schaack S. Understanding Ebola: the 2014 epidemic. Glob Health. 2016;12(1):53.CrossRef
7.
Leligdowicz A, Fischer 2nd WA, Uyeki TM, Fletcher TE, Adhikari NK, Portella G, Lamontagne F, Clement C, Jacob ST, Rubinson L, et al. Ebola virus disease and critical illness. Critical Care (London, England). 2016;20(1):217.CrossRef
8.
Rivera A, Messaoudi I. Molecular mechanisms of Ebola pathogenesis. J Leukoc Biol. 2016;100(5):889–904.
9.
Brainard J, Pond K, Hooper L, Edmunds K, Hunter P. Presence and persistence of Ebola or Marburg virus in patients and survivors: a rapid systematic review. PLoS Negl Trop Dis. 2016;10(2):e0004475.PubMedPubMedCentralCrossRef
10.
Glaze ER, Roy MJ, Dalrymple LW, Lanning LL. A comparison of the pathogenesis of Marburg virus disease in humans and nonhuman primates and evaluation of the suitability of these animal models for predicting clinical efficacy under the ‘Animal Rule’. Comp Med. 2015;65(3):241–59.PubMedPubMedCentral
11.
Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. 2015;13(11):663–76.PubMedPubMedCentralCrossRef
12.
Pigott DM, Golding N, Mylne A, Huang Z, Weiss DJ, Brady OJ, Kraemer MU, Hay SI. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg. 2015;109(6):366–78.PubMedPubMedCentralCrossRef
13.
Rodhain F. [Bats and viruses: complex relationships]. Bull Soc Pathol Exot (1990). 2015;108(4):272–89.CrossRef
14.
El-Bahnasawy MM, Megahed LA, Abdalla Saleh HA, Morsy TA. Lassa fever or lassa hemorrhagic fever risk to humans from rodent-borne zoonoses. J Egypt Soc Parasitol. 2015;45(1):61–70.PubMedCrossRef
15.
Mylne AQ, Pigott DM, Longbottom J, Shearer F, Duda KA, Messina JP, Weiss DJ, Moyes CL, Golding N, Hay SI. Mapping the zoonotic niche of Lassa fever in Africa. Trans R Soc Trop Med Hyg. 2015;109(8):483–92.PubMedPubMedCentralCrossRef
16.
Malik M, Elkholy AA, Khan W, Hassounah S, Abubakar A, Minh NT, Mala P. Middle East respiratory syndrome coronavirus: current knowledge and future considerations. East Mediterr Health J. 2016;22(7):537–46.PubMed
17.
Mo Y, Fisher D. A review of treatment modalities for Middle East Respiratory Syndrome. J Antimicrob Chemother. 2016;71(12):3340–50.
18.
19.
20.
Vijay R, Perlman S. Middle East respiratory syndrome and severe acute respiratory syndrome. Curr Opin Virol. 2016;16:70–6.PubMedCrossRef
21.
Angeletti S, Lo Presti A, Cella E, Ciccozzi M. Molecular epidemiology and phylogeny of nipah virus infection: a mini review. Asian Pac J Trop Med. 2016;9(7):630–4.PubMedCrossRef
22.
23.
Escaffre O, Borisevich V, Rockx B. Pathogenesis of Hendra and Nipah virus infection in humans. J Infect Dev Ctries. 2013;7(4):308–11.PubMedCrossRef
24.
Han HJ, Wen HL, Zhou CM, Chen FF, Luo LM, Liu JW, Yu XJ. Bats as reservoirs of severe emerging infectious diseases. Virus Res. 2015;205:1–6.PubMedCrossRef
25.
Baba M, Masiga DK, Sang R, Villinger J. Has Rift Valley fever virus evolved with increasing severity in human populations in East Africa? Emerg Microbes Infect. 2016;5:e58.PubMedPubMedCentralCrossRef
26.
Bird BH, McElroy AK. Rift valley fever virus: unanswered questions. Antivir Res. 2016;132:274–80.PubMedCrossRef
27.
Lorenzo G, Lopez-Gil E, Warimwe GM, Brun A. Understanding Rift Valley fever: contributions of animal models to disease characterization and control. Mol Immunol. 2015;66(1):78–88.PubMedCrossRef
28.
Mansfield KL, Banyard AC, McElhinney L, Johnson N, Horton DL, Hernandez-Triana LM, Fooks AR. Rift valley fever virus: a review of diagnosis and vaccination, and implications for emergence in Europe. Vaccine. 2015;33(42):5520–31.PubMedCrossRef
29.
Wiley CA, Bhardwaj N, Ross TM, Bissel SJ. Emerging infections of CNS: avian influenza a virus, rift valley fever virus and human parechovirus. Brain Pathol (Zurich, Switzerland). 2015;25(5):634–50.CrossRef
30.
Takahashi-Omoe H, Omoe K. Worldwide trends in infectious disease research revealed by a new bibliometric method. INTECH Open Access Publisher; 2012.
31.
Unkel S, Farrington C, Garthwaite PH, Robertson C, Andrews N. Statistical methods for the prospective detection of infectious disease outbreaks: a review. J R Stat Soc A Stat Soc. 2012;175(1):49–82.CrossRef
32.
Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008;22(2):338–42.PubMedCrossRef
33.
34.
Garg K, Kumar S. Bibliometrics of global Ebola Virus Disease research as seen through Science Citation Index Expanded during 1987–2015. Travel Med Infect Dis. 2016.
35.
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–66.PubMedCrossRef
36.
Ramakrishnan J, Sankar GR. Bibliometric Analysis of Literature on Ebola (1995–2014). Indian J Libr Inf Sci. 2015;9(2):133.
37.
Chiu W-T, Huang J-S, Ho Y-S. Bibliometric analysis of severe acute respiratory syndrome-related research in the beginning stage. Scientometrics. 2004;61(1):69–77.CrossRef
38.
GUAN J, LI Z-f, CHEN W-k, ZHONG W-j. Bibliometric analysis of SARS literature [J]. Chin J Med Libr. 2004;2:037.
39.
Safahieh H, Sanni S, Zainab A: International Contribution to Nipah Virus Research 1999–2010. arXiv preprint arXiv:13015384 2013.
40.
Sanni S, Safahieh H, Zainab A, Abrizah A, Raj R. Evaluating the growth pattern and relative performance in Nipah virus research from 1999 to 2010. Malaysi J Libr Inf Sci. 2013;18(2):14–24.
41.
Cox R, McIntyre K, Sanchez J, Setzkorn C, Baylis M, Revie C: Comparison of the h‐Index Scores Among Pathogens Identified as Emerging Hazards in North America. Transboundary and emerging diseases 2014.
42.
Allen T, Parker M. Will increased funding for neglected tropical diseases really make poverty history? Lancet. 2012;379(9821):1097–8.PubMedCrossRef
43.
Eurosurveillance editorial team. The European Union provides funding to strengthen the protection against zoonoses and animal diseases. Euro Surveill. 2011;16(46).
44.
Hempelmann E, Tesarowicz I, Oleksyn BJ. From onions to artemisinin. Brief history of malaria chemotherapy. Pharm Unserer Zeit. 2009;38(6):500–7.PubMedCrossRef
45.
White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41(7):1413–22.PubMedPubMedCentral
46.
Brown G. Artemisinin and a new generation of antimalarial drugs. Educ Chem. 2006;43(4):97–9.
47.
Callaway E, Cyranoski D. Anti-parasite drugs sweep Nobel prize in medicine 2015. Nature. 2015;526(7572):174–5.PubMedCrossRef
48.
Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985;228(4703):1049–55.PubMedCrossRef
49.
Maltezou H, Andonova L, Andraghetti R, Bouloy M, Ergonul O, Jongejan F, Kalvatchev N, Nichol S, Niedrig M, Platonov A. Crimean-Congo hemorrhagic fever in Europe: current situation calls for preparedness. EuroSurveill. 2010;15(10):1–4.
50.
Al-Abaidani IS, Al-Maani AS, Al-Kindi HS, Al-Jardani AK, Abdel-Hady DM, Zayed BE, Al-Harthy KS, Al-Shaqsi KH, Al-Abri SS. Overview of preparedness and response for Middle East respiratory syndrome coronavirus (MERS-CoV) in Oman. Int J Infect Dis. 2014;29:309–10.PubMedCrossRef
51.
de Sousa R, Reusken C, Koopmans M. MERS coronavirus: data gaps for laboratory preparedness. J Clin Virol. 2014;59(1):4–11.PubMedCrossRef
52.
Ng OW, Tan YJ. Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks - Implications for coronavirus vaccine development. Hum Vaccin Immunother. 2016;13(1):186–89.
53.
Fleischer T, Kevany S, Benatar SR. Will escalating spending on HIV treatment displace funding for treatment of other diseases? S Afr Med J. 2010;100(1):32–4.PubMed
54.
Head MG, Fitchett JR, Derrick G, Wurie FB, Meldrum J, Kumari N, Beattie B, Counts CJ, Atun R. Comparing research investment to United Kingdom institutions and published outputs for tuberculosis, HIV and malaria: a systematic analysis across 1997–2013. Health Res Policy Syst. 2015;13(1):63.PubMedPubMedCentralCrossRef
55.
Sipahi O, Sipahi H, Tasbakan M, Pullukcu H, Arda B, Yamazhan T, Ulusoy S. Bibliometric analysis of publications in infectious diseases and clinical microbiology areas: Which coutries led in 1996–2011 and 2011 periods? Int J Infect Dis. 2014;21:245.CrossRef
56.
Ramos J, González-Alcaide G, Gutiérrez F. [Bibliometric analysis of the Spanish scientific production in Infectious Diseases and Microbiology]. Enferm Infecc Microbiol Clin. 2016;34(3):166–76.PubMedCrossRef
57.
Coker RJ, Hunter BM, Rudge JW, Liverani M, Hanvoravongchai P. Emerging infectious diseases in southeast Asia: regional challenges to control. Lancet. 2011;377(9765):599–609.PubMedCrossRef
58.
Chen T, Leung RK-K, Liu R, Chen F, Zhang X, Zhao J, Chen S. Risk of imported Ebola virus disease in China. Travel Med Infect Dis. 2014;12(6):650–8.PubMedCrossRef
59.
Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba NF, Soropogui B, Sow MS, Keïta S, De Clerck H. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371(15):1418–25.PubMedCrossRef
60.
Chan M. Ebola virus disease in West Africa—no early end to the outbreak. N Engl J Med. 2014;371(13):1183–5.PubMedCrossRef
61.
Dixon MG, Schafer IJ. Ebola viral disease outbreak—West Africa, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(25):548–51.PubMed
62.
Himeidan YE, Kweka EJ, Mahgoub MM, El Rayah el A, Ouma JO. Recent outbreaks of rift valley Fever in East Africa and the middle East. Front Public Health. 2014;2:169.PubMedPubMedCentralCrossRef
63.
64.
Hunter JC, Nguyen D, Aden B, Al Bandar Z, Al Dhaheri W, Abu Elkheir K, Khudair A, Al Mulla M, El Saleh F, Imambaccus H, et al. Transmission of middle east respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis. 2016;22(4):647–56.PubMedPubMedCentralCrossRef
65.
Kim KM, Ki M. Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary’s Hospital. Epidemiol Health. 2015;37:e2015041.PubMedPubMedCentralCrossRef
66.
Mishra B. Combating the spread of Middle East respiratory syndrome coronavirus: Indian perspective. Indian J Med Microbiol. 2016;34(2):135–6.PubMedCrossRef
67.
68.
Park SH. Outbreaks of middle east respiratory syndrome in Two hospitals initiated by a single patient in daejeon, south Korea. BMC Infect Dis. 2016;48(2):99–107.CrossRef
69.
Poletto C, Colizza V, Boelle PY. Quantifying spatiotemporal heterogeneity of MERS-CoV transmission in the Middle East region: a combined modelling approach. Epidemics. 2016;15:1–9.PubMedCrossRef
70.
Zumla A, Alagaili AN, Cotten M, Azhar EI. Infectious diseases epidemic threats and mass gatherings: refocusing global attention on the continuing spread of the Middle East Respiratory syndrome coronavirus (MERS-CoV). BMC Med. 2016;14(1):132.PubMedPubMedCentralCrossRef
71.
Sweileh WM, Al-Jabi SW, Sawalha AF, Zyoud SH. Bibliometric profile of the global scientific research on autism spectrum disorders. SpringerPlus. 2016;5(1):1480.PubMedPubMedCentralCrossRef
72.
Leblebicioglu H, Sunbul M, Memish ZA, Al-Tawfiq JA, Bodur H, Ozkul A, Gucukoglu A, Chinikar S, Hasan Z. Consensus report: preventive measures for Crimean-Congo hemorrhagic fever during Eid-al-adha festival. Int J Infect Dis. 2015;38:9–15.PubMedCrossRef
73.
Mohamed Al Dabal L, Rahimi Shahmirzadi MR, Baderldin S, Abro A, Zaki A, Dessi Z, Al Eassa E, Khan G, Shuri H, Alwan AM. Crimean-Congo hemorrhagic fever in Dubai, United Arab Emirates, 2010: case report. Iran Red Crescent Med J. 2016;18(8):e38374.PubMedPubMedCentralCrossRef
74.
Pourhossein B, Irani AD, Mostafavi E. Major infectious diseases affecting the Afghan immigrant population of Iran: a systematic review and meta-analysis. Epidemiol Health. 2015;37:e2015002.PubMedPubMedCentralCrossRef
75.
Saleem J, Usman M, Nadeem A, Sethi SA, Salman M. Crimean-Congo hemorrhagic fever: a first case from Abbottabad, Pakistan. Int J Infect Dis. 2009;13(3):e121–3.PubMedCrossRef
76.
Yadav PD, Gurav YK, Mistry M, Shete AM, Sarkale P, Deoshatwar AR, Unadkat VB, Kokate P, Patil DY, Raval DK, et al. Emergence of Crimean-Congo hemorrhagic fever in Amreli District of Gujarat State, India, June to July 2013. Int J Infect Dis. 2014;18:97–100.PubMedCrossRef
77.
Yilmaz R, Ozcetin M, Erkorkmaz U, Ozer S, Ekici F. Public knowledge and attitude toward Crimean Congo hemorrhagic fever in Tokat Turkey. Iran J Arthropod Borne Dis. 2009;3(2):12–7.PubMedPubMedCentral
78.
Lau AL, Chi I, Cummins RA, Lee TM, Chou K-L, Chung LW. The SARS (Severe Acute Respiratory Syndrome) pandemic in Hong Kong: effects on the subjective wellbeing of elderly and younger people. Aging Mental Health. 2008;12(6):746–60.PubMedCrossRef
79.
Lee K. How the Hong Kong government lost the public trust in SARS: insights for government communication in a health crisis. Public Relat Rev. 2009;35(1):74–6.CrossRef
80.
Keogh-Brown MR, Smith RD. The economic impact of SARS: how does the reality match the predictions? Health Policy. 2008;88(1):110–20.PubMedCrossRef
81.
Ohuabunwo C, Ameh C, Oduyebo O, Ahumibe A, Mutiu B, Olayinka A, Gbadamosi W, Garcia E, Nanclares C, Famiyesin W et al. Clinical profile and containment of the Ebola virus disease outbreak in two large West African cities, Nigeria, July-September 2014. Int J Infect Dis. 2016;53:23–29.
82.
Rosello A, Mossoko M, Flasche S, Van Hoek AJ, Mbala P, Camacho A, Funk S, Kucharski A, Ilunga BK, Edmunds WJ et al. Ebola virus disease in the Democratic Republic of the Congo, 1976–2014. eLife 2015;4.
83.
Safari S, Baratloo A, Rouhipour A, Ghelichkhani P, Yousefifard M. Ebola hemorrhagic fever as a public health emergency of international concern; a review article. Emergency (Tehran, Iran). 2015;3(1):3–7.
84.
Centers for Disease Control and Prevention (CDC). Rift Valley fever outbreak--Kenya, November 2006-January. MMWR Morb Mortal Wkly Rep 2007. 2007;56(4):73–6.
85.
Faye O, Diallo M, Diop D, Bezeid OE, Ba H, Niang M, Dia I, Mohamed SA, Ndiaye K, Diallo D, et al. Rift Valley fever outbreak with East-Central African virus lineage in Mauritania, 2003. Emerg Infect Dis. 2007;13(7):1016–23.PubMedPubMedCentralCrossRef
86.
Munyua P, Murithi RM, Wainwright S, Githinji J, Hightower A, Mutonga D, Macharia J, Ithondeka PM, Musaa J, Breiman RF, et al. Rift Valley fever outbreak in livestock in Kenya, 2006–2007. AmJTrop Med Hyg. 2010;83(2 Suppl):58–64.CrossRef
87.
88.
Sweileh WM, Shraim NY, Al-Jabi SW, Sawalha AF, AbuTaha AS, Zyoud SH. Bibliometric analysis of global scientific research on carbapenem resistance (1986–2015). Ann Clin Microbiol Antimicrob. 2016;15(1):56.PubMedPubMedCentralCrossRef
89.
Sweileh WM, Shraim NY, Al-Jabi SW, Sawalha AF, Rahhal B, Khayyat RA, Zyoud SH. Assessing worldwide research activity on probiotics in pediatrics using Scopus database: 1994–2014. World Allergy Organ J. 2016;9:25.PubMedPubMedCentralCrossRef
90.
91.
Sweileh WM, Zyoud SH, Al-Jabi SW, Sawalha AF, Shraim NY. Drinking and recreational water-related diseases: a bibliometric analysis (1980–2015). Ann Occup Environ Med. 2016;28(1):40.PubMedPubMedCentralCrossRef
92.
Mongeon P, Paul-Hus A. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometrics. 2016;106(1):213–28.CrossRef
93.
Drosten C, Günther S, Preiser W, Van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RAM, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–76.PubMedCrossRef
94.
Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, Nicholls J, Yee WKS, Yan WW, Cheung MT, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319–25.PubMedCrossRef
95.
Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Peñaranda S, Bankamp B, Maher K, Chen MH, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300(5624):1394–9.PubMedCrossRef
96.
Marra MA, Jones SJM, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YSN, Khattra J, Asano JK, Barber SA, Chan SY, et al. The genome sequence of the SARS-associated coronavirus. Science. 2003;300(5624):1399–404.PubMedCrossRef
97.
Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–94.PubMedCrossRef
98.
Li W, Moore MJ, Vasllieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greeneugh TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.PubMedCrossRef
99.
Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science. 2003;302(5643):276–8.PubMedCrossRef
100.
Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348(20):1995–2005.PubMedCrossRef
101.
Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310(5748):676–9.PubMedCrossRef
102.
Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, Seto WH, Yam LY, Cheung TM, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1977–85.PubMedCrossRef
103.
Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LLM, Guan Y, Rozanov M, Spaan WJM, Gorbalenya AE. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol. 2003;331(5):991–1004.PubMedCrossRef
104.
Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Délicat A, Paweska JT, Gonzalez JP, Swanepoel R. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438(7068):575–6.PubMedCrossRef
105.
106.
Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. J Am Med Assoc. 2003;289(21):2801–9.CrossRef
107.
Lau SKP, Woo PCY, Li KSM, Huang Y, Tsoi HW, Wong BHL, Wong SSY, Leung SY, Chan KH, Yuen KY. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005;102(39):14040–5.PubMedPubMedCentralCrossRef
108.
Fouchier RAM, Kuiken T, Schutten M, Van Amerongen G, Van Doornum GJJ, Van Den Hoogen BG, Peiris M, Lim W, Stöhr K, Osterhaus ADME. Koch’s postulates fulfilled for SARS virus. Nature. 2003;423(6937):240.PubMedCrossRef
109.
Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, Gopalakrishna G, Chew SK, Tan CC, Samore MH, et al. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003;300(5627):1966–70.PubMedPubMedCentralCrossRef
110.
Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, Abu-Raddad LJ, Ho LM, Thach TQ, Chau P, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet. 2003;361(9371):1761–6.PubMedCrossRef
111.
Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408(6812):605–9.PubMedCrossRef
112.
Sullivan NJ, Geisbert TW, Gelsbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424(6949):681–4.PubMedCrossRef
113.
Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–90.PubMedCrossRef
114.
Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–4.PubMedCrossRef
115.
Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A. 2004;101(17):6641–6.PubMedPubMedCentralCrossRef
116.
Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998;251(1):28–37.PubMedCrossRef
117.
Gao W, Tamin A, Soloff A, D’Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362(9399):1895–6.PubMedCrossRef
118.
Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat Rev Immunol. 2003;3(8):677–85.PubMedCrossRef
119.
Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002;8(5):503–7.PubMedPubMedCentralCrossRef
120.
Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol. 2003;32(6):567–82.PubMedCrossRef
121.
Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis. 2007;196(SUPPL. 2):S430–7.
122.
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66.PubMedCrossRef
123.
Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998;246(1):134–44.PubMedCrossRef
124.
Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006;13(11):1267–77.PubMedPubMedCentralCrossRef
125.
Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol. 2009;83(14):7296–304.PubMedPubMedCentralCrossRef
126.
Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Ströher U, Fernando L, Daddario KM, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2(6):0537–45.CrossRef
127.
He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773–81.PubMedCrossRef
128.
Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7(5):393–400.PubMedCrossRef
129.
Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol. 2004;78(2):834–40.PubMedPubMedCentralCrossRef
130.
Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005;79(5):2678–88.PubMedPubMedCentralCrossRef
Metadata
Title
Global research trends of World Health Organization’s top eight emerging pathogens
Author
Waleed M. Sweileh
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2017
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/s12992-017-0233-9

Other articles of this Issue 1/2017

Globalization and Health 1/2017 Go to the issue

Research

Operational and implementation research within Global Fund to Fight AIDS, Tuberculosis and Malaria grants: a situation analysis in six countries

Research

“I cry every day and night, I have my son tied in chains”: physical restraint of people with schizophrenia in community settings in Ethiopia

Research

Setting performance-based financing in the health sector agenda: a case study in Cameroon

Research

In which developing countries are patents on essential medicines being filed?

Research

Operationalizing mHealth to improve patient care: a qualitative implementation science evaluation of the WelTel texting intervention in Canada and Kenya

Editorial

Priority gaps and promising areas in maternal health research in low- and middle-income countries: summary findings of a mapping of 2292 publications between 2000 and 2012